Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi Pasteur SA
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated either with an Inactivated Influenza Vaccine Administered via the Intradermal Route or an Inactivated Influenza Vaccine Administered via the Intramuscular Route
- To describe the cellular immune response per age group (adults or elderly) and vaccine group (ID influenza or IM comparator vaccines) before vaccination, and, 7 days, 10 days, 14 days, 21 days, 180 ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of the Investigational Inactivated, Split-Virion Influenza Vaccine 15 µg Administered by the Intradermal Route in Comparison with the Intramuscular Reference Vaccine Vaxigrip® in 50 to 59 Years old Adults
• To demonstrate that the ID investigational vaccine is at least as immunogenic as the IM reference vaccine in terms of geometric mean titer (GMT) after vaccination. • If non-inferiority is demonstr...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Lot-to-Lot Consistency Study of the Investigational, Split-virion, Inactivated Influenza Vaccine, Administered by the Intradermal Route in Adults
To demonstrate that the three different industrial lots of the intradermal (ID) investigational vaccine induce an equivalent immune response.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children
To describe the safety of the 9µg formulation of the inactivated, split-virion influenza vaccine administered by the intradermal (ID) route in children aged 6 to 35 months and 3 to 8 years.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months
• To describe the immune response of each candidate vaccine 21 days after each vaccination by hemagglutination inhibition (HAI) and seroneutralization (SN) testing in all subjects. • To describe the a...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3